A pathway for luteinizing hormone releasing-hormone self-potentiation

Cross-talk with the progesterone receptor

D. W. Waring, Judith L Turgeon

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

This study investigates the signaling pathways that lead to acute augmentation of secretagogue-induced LH secretion, the physiologically relevant manifestation of which is LHRH self-potentiation. The consequence of LHRH self-potentiation is an augmented LH secretory response to subsequent exposure to the peptide. Although the mechanism for LHRH self-potentiation remains obscure, the second messenger cAMP and the steroid hormone progesterone share common characteristics in their acute augmentation of secretagogue-induced pituitary LH secretion, suggesting that cross-talk between the peptide and steroid hormone pathways may occur. The progesterone receptor would represent a point of convergence of several effectors known to augment secretagogue-induced LH secretion. In rat anterior pituitary cells cultured in the absence of progesterone, it was found that the progesterone receptor antagonist RU486 (2 nM) inhibits LHRH self-potentiation induced by hourly pulses of 1 nM LHRH. In the absence of added progesterone, RU486 also suppresses the augmentation of LHRH-stimulated LH secretion which is a consequence of increasing [cAMP]i with either 8-bromo-cAMP (1 mM) or forskolin (1 μM) treatment. The extent of the suppression of the cAMP action in the presence of RU486 is similar to that found with the RNA synthesis inhibitor, actinomycin D. The data are consistent with the hypothesis that a LHRH-stimulated protein kinase A cascade acts, in part, through transcriptional activation of the progesterone receptor. It is concluded that the mechanism of LHRH self-potentiation requires cross-talk with the progesterone receptor.

Original languageEnglish (US)
Pages (from-to)3275-3282
Number of pages8
JournalEndocrinology
Volume130
Issue number6
StatePublished - Jun 1992

Fingerprint

Progesterone Receptors
Gonadotropin-Releasing Hormone
Progesterone
Steroids
Nucleic Acid Synthesis Inhibitors
8-Bromo Cyclic Adenosine Monophosphate
Peptide Hormones
Dactinomycin
Second Messenger Systems
Colforsin
Cyclic AMP-Dependent Protein Kinases
Transcriptional Activation
Cultured Cells
Hormones
Peptides

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

A pathway for luteinizing hormone releasing-hormone self-potentiation : Cross-talk with the progesterone receptor. / Waring, D. W.; Turgeon, Judith L.

In: Endocrinology, Vol. 130, No. 6, 06.1992, p. 3275-3282.

Research output: Contribution to journalArticle

@article{551999d260b841c58007612ed2dc7161,
title = "A pathway for luteinizing hormone releasing-hormone self-potentiation: Cross-talk with the progesterone receptor",
abstract = "This study investigates the signaling pathways that lead to acute augmentation of secretagogue-induced LH secretion, the physiologically relevant manifestation of which is LHRH self-potentiation. The consequence of LHRH self-potentiation is an augmented LH secretory response to subsequent exposure to the peptide. Although the mechanism for LHRH self-potentiation remains obscure, the second messenger cAMP and the steroid hormone progesterone share common characteristics in their acute augmentation of secretagogue-induced pituitary LH secretion, suggesting that cross-talk between the peptide and steroid hormone pathways may occur. The progesterone receptor would represent a point of convergence of several effectors known to augment secretagogue-induced LH secretion. In rat anterior pituitary cells cultured in the absence of progesterone, it was found that the progesterone receptor antagonist RU486 (2 nM) inhibits LHRH self-potentiation induced by hourly pulses of 1 nM LHRH. In the absence of added progesterone, RU486 also suppresses the augmentation of LHRH-stimulated LH secretion which is a consequence of increasing [cAMP]i with either 8-bromo-cAMP (1 mM) or forskolin (1 μM) treatment. The extent of the suppression of the cAMP action in the presence of RU486 is similar to that found with the RNA synthesis inhibitor, actinomycin D. The data are consistent with the hypothesis that a LHRH-stimulated protein kinase A cascade acts, in part, through transcriptional activation of the progesterone receptor. It is concluded that the mechanism of LHRH self-potentiation requires cross-talk with the progesterone receptor.",
author = "Waring, {D. W.} and Turgeon, {Judith L}",
year = "1992",
month = "6",
language = "English (US)",
volume = "130",
pages = "3275--3282",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - A pathway for luteinizing hormone releasing-hormone self-potentiation

T2 - Cross-talk with the progesterone receptor

AU - Waring, D. W.

AU - Turgeon, Judith L

PY - 1992/6

Y1 - 1992/6

N2 - This study investigates the signaling pathways that lead to acute augmentation of secretagogue-induced LH secretion, the physiologically relevant manifestation of which is LHRH self-potentiation. The consequence of LHRH self-potentiation is an augmented LH secretory response to subsequent exposure to the peptide. Although the mechanism for LHRH self-potentiation remains obscure, the second messenger cAMP and the steroid hormone progesterone share common characteristics in their acute augmentation of secretagogue-induced pituitary LH secretion, suggesting that cross-talk between the peptide and steroid hormone pathways may occur. The progesterone receptor would represent a point of convergence of several effectors known to augment secretagogue-induced LH secretion. In rat anterior pituitary cells cultured in the absence of progesterone, it was found that the progesterone receptor antagonist RU486 (2 nM) inhibits LHRH self-potentiation induced by hourly pulses of 1 nM LHRH. In the absence of added progesterone, RU486 also suppresses the augmentation of LHRH-stimulated LH secretion which is a consequence of increasing [cAMP]i with either 8-bromo-cAMP (1 mM) or forskolin (1 μM) treatment. The extent of the suppression of the cAMP action in the presence of RU486 is similar to that found with the RNA synthesis inhibitor, actinomycin D. The data are consistent with the hypothesis that a LHRH-stimulated protein kinase A cascade acts, in part, through transcriptional activation of the progesterone receptor. It is concluded that the mechanism of LHRH self-potentiation requires cross-talk with the progesterone receptor.

AB - This study investigates the signaling pathways that lead to acute augmentation of secretagogue-induced LH secretion, the physiologically relevant manifestation of which is LHRH self-potentiation. The consequence of LHRH self-potentiation is an augmented LH secretory response to subsequent exposure to the peptide. Although the mechanism for LHRH self-potentiation remains obscure, the second messenger cAMP and the steroid hormone progesterone share common characteristics in their acute augmentation of secretagogue-induced pituitary LH secretion, suggesting that cross-talk between the peptide and steroid hormone pathways may occur. The progesterone receptor would represent a point of convergence of several effectors known to augment secretagogue-induced LH secretion. In rat anterior pituitary cells cultured in the absence of progesterone, it was found that the progesterone receptor antagonist RU486 (2 nM) inhibits LHRH self-potentiation induced by hourly pulses of 1 nM LHRH. In the absence of added progesterone, RU486 also suppresses the augmentation of LHRH-stimulated LH secretion which is a consequence of increasing [cAMP]i with either 8-bromo-cAMP (1 mM) or forskolin (1 μM) treatment. The extent of the suppression of the cAMP action in the presence of RU486 is similar to that found with the RNA synthesis inhibitor, actinomycin D. The data are consistent with the hypothesis that a LHRH-stimulated protein kinase A cascade acts, in part, through transcriptional activation of the progesterone receptor. It is concluded that the mechanism of LHRH self-potentiation requires cross-talk with the progesterone receptor.

UR - http://www.scopus.com/inward/record.url?scp=0026647299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026647299&partnerID=8YFLogxK

M3 - Article

VL - 130

SP - 3275

EP - 3282

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 6

ER -